• About Us
    • Company Overview
    • Leadership
    • Board of Directors
    • Business Advisors
    • Scientific Advisory Board
    • Corporate Governance
  • Our Focus
    • COVID-19 and CVD
    • Acute Myocarditis
    • Heart Failure
    • R&D Partners
    • Our Science
    • Resources
  • Products
  • Investors
    • Events & Presentations
    • Press Releases
    • Analyst Coverage
    • Stock Information
    • Filings & Financials
    • AGM
    • Contact Us
News

Cardiol Therapeutics to Participate in Upcoming Virtual Investor Conferences

January 07, 2021

Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx™

December 22, 2020

Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company’s Phase II/III Outcomes Trial in High-risk Patients Hospitalized with COVID-19

December 15, 2020

Cardiol Therapeutics’ Cortalex™ CBD Now Available Exclusively Online at Medical Cannabis by Shoppers Inc.

October 20, 2020

Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial

September 25, 2020

Cardiol Therapeutics to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference

September 15, 2020

Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx™

August 26, 2020

Cardiol Therapeutics Appoints CNBC Market Analyst Steven Grasso as Business Advisor

June 29, 2020

David Elsley Files Early Warning Report for Cardiol Therapeutics

June 25, 2020

Cardiol Therapeutics Closes $17.25 Million Bought Deal Offering, Including Full Exercise of the Over-Allotment Option

June 04, 2020
Page 1 of 712345...»Last »
  • About Us
  • Our Focus
  • Investors
  • Contact

TSX: CRDL OTCQX: CRTPF

 

Sign up to receive the latest news from Cardiol Therapeutics

© 2021 Cardiol Therapeutics Inc. All rights reserved.      Terms of Use      Privacy Policy